Suppr超能文献

应用瞬时弹性成像和 FibroTest 监测接受甲氨蝶呤治疗银屑病患者的肝毒性。

The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

机构信息

The Charles Centre, Dermatology Department, St Vincent's University Hospital, Dublin, Ireland.

Liver Unit, St Vincent's University Hospital, Dublin, Ireland.

出版信息

JAMA Dermatol. 2014 Aug;150(8):856-62. doi: 10.1001/jamadermatol.2013.9336.

Abstract

IMPORTANCE

There is a need for noninvasive tools to monitor hepatotoxicity in patients with psoriasis who are receiving methotrexate sodium.

OBJECTIVE

To evaluate the use of transient elastography (TE) and FibroTest (FibroSURE in the United States), an indirect serum marker of fibrosis, in this population.

DESIGN, SETTING, AND PARTICIPANTS: Patients receiving methotrexate therapy for psoriasis between January 2008 and September 2009 were recruited from a dermatology outpatient department. Transient elastography and FibroTest were performed, and patients with abnormal results were considered for liver biopsy. Serial procollagen III peptide (PIIINP) results were recorded.

INTERVENTIONS

Transient elastography uses pulse-echo ultrasonography to measure liver stiffness, and this result is an indirect measure of hepatic fibrosis. FibroTest is an indirect serum marker of hepatic fibrosis.

MAIN OUTCOMES AND MEASURES

Procollagen III peptide, TE, and FibroTest results, as well as the need for liver biopsy in this cohort.

RESULTS

Seventy-seven patients (41 male [53%]) were included. Fifty (65%) patients had a valid TE assessment, and 9 (18%) had an abnormal result (range, 7.1-11.3 kPa). Being overweight or obese increased the possibility of obtaining an invalid TE result significantly (P = .01). On univariate analysis body mass index (r = 0.40, P = .005) and age (r = 0.52, P = .005) were correlated with abnormal TE results. Seventy-one patients received a FibroTest and 11 of 70 analyzed (16%) had an abnormal result (METAVIR score >F1). Age (r = 0.31, P = .009), cumulative methotrexate dose (r = 0.31, P = .01), and duration of methotrexate therapy (r = 0.36, P = .002) were correlated with abnormal FibroTest results. There was no correlation between PIIINP levels and TE results or between PIIINP levels and FibroTest results. Steatosis was demonstrated in all 5 patients who received liver biopsies during the study. Two patients had hepatic fibrosis, with 1 showing a sinusoidal pattern of fibrosis attributed to steatohepatitis.

CONCLUSIONS AND RELEVANCE

Transient elastography and FibroTest are effective noninvasive tools for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis. We propose that the need for liver biopsy could be reduced if abnormalities in at least 2 tests (serial PIIINP, TE, or FibroTest) are required before biopsy is considered. This strategy should be evaluated in prospective studies.

摘要

重要性

对于正在接受甲氨蝶呤钠治疗的银屑病患者,需要非侵入性的工具来监测肝毒性。

目的

评估瞬时弹性成像(TE)和 FibroTest(美国的 FibroSURE),一种纤维化的间接血清标志物,在这一人群中的应用。

设计、地点和参与者:2008 年 1 月至 2009 年 9 月期间,从皮肤科门诊招募了正在接受甲氨蝶呤治疗银屑病的患者。进行了瞬时弹性成像和 FibroTest,对结果异常的患者考虑进行肝活检。记录了连续的前胶原 III 肽(PIIINP)结果。

干预措施

瞬时弹性成像使用脉冲回声超声来测量肝硬度,这是肝纤维化的间接测量。FibroTest 是一种纤维化的间接血清标志物。

主要结果和测量指标

在这组患者中,前胶原 III 肽、TE 和 FibroTest 的结果,以及肝活检的需要。

结果

77 例患者(41 例男性[53%])被纳入研究。50 例(65%)患者的 TE 评估有效,9 例(18%)结果异常(范围为 7.1-11.3kPa)。超重或肥胖显著增加了获得无效 TE 结果的可能性(P = .01)。在单因素分析中,体重指数(r = 0.40,P = .005)和年龄(r = 0.52,P = .005)与异常 TE 结果相关。71 例患者接受了 FibroTest 检查,70 例分析中有 11 例(16%)结果异常(METAVIR 评分>F1)。年龄(r = 0.31,P = .009)、累积甲氨蝶呤剂量(r = 0.31,P = .01)和甲氨蝶呤治疗时间(r = 0.36,P = .002)与异常 FibroTest 结果相关。PIIINP 水平与 TE 结果之间或与 FibroTest 结果之间均无相关性。在研究期间接受肝活检的 5 例患者中均显示有脂肪变性。2 例患者有肝纤维化,其中 1 例表现为归因于脂肪性肝炎的窦状纤维化模式。

结论和相关性

瞬时弹性成像和 FibroTest 是监测接受甲氨蝶呤治疗银屑病患者肝毒性的有效非侵入性工具。我们建议,如果在考虑肝活检之前,至少有 2 项检查(连续的 PIIINP、TE 或 FibroTest)出现异常,则可以减少肝活检的需求。这一策略应该在前瞻性研究中进行评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验